In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Eva Chamorro, PhD, MSc, points out that myopia control spectacle lenses affect the diurnal rhythms in the AL in young adult human and produced a small short-term increase in the AL that varies in intensity and time interval for each of the 3 studied lenses.
THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.
Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
Treatments include tinted spectacles and/or contact lenses, low-vision aids, atropine drops, and patching for amblyopia, as well as eye muscle surgery for the nystagmus or any anomalous head posture and associated strabismus.
The intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Mamoru Ogawa, MD, noted that investigators have found that the choroidal and central corneal thicknesses increased over a very short period of time following intensive outdoor activity.
Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.
According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.
According to research, many patients with retinal vein occlusion have vision benefits, but require long-term monitoring and treatment
Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss future directions and unmet needs in the field of retinal eye disease.
Key opinion leaders discuss the barriers to co-management of retinal eye disease.
Researchers at the University of Southern California have stimulated the retinas of blind mice using focused ultrasound technology.
According to the company, post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints. The company plans to discuss findings with regulators in Q3.
Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the transition of care from ophthalmologist to optometrist once a patient has completed active treatment for retinal eye disease.
Experts in the field of retinal eye disorders discuss the role of injectable anti-VEGF inhibitors and how they have changed the treatment landscape.
According to review, patients with mild DR at baseline fare better
Impact of native lipids on rhodopsin signaling and regeneration opens door to GPCR drug discovery in native membrane environments
The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.
According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.
Dilsher S. Dhoot, MD, leads a discussion about the treatment landscape of retinal eye disorders.
Key opinion leaders discuss how co-management affects the patient-provider relationship in the treatment of retinal eye disorders.
According to the company, the modifier gene therapy candidate is for the treatment of retinitis pigmentosa resulting from mutations in the nuclear receptor subfamily 2 group E member 3 and Rhodopsin genes.
Investigators at the International Center for Materials Nanoarchitectonics have developed the first-ever artificial retinal device that increases the edge contrast between lighter and darker areas of an image, using ionic migration and interaction within solid.
The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.
